Editorial: Role of HSV-2 suppressive therapy for HIV prevention

Future Microbiology

Volumn 4, Issue 9, 2009, Pages 1095-1097

  Reynolds, Steven J ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

CLINICAL TRIAL; DISEASE ASSOCIATION; EDITORIAL; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MIXED INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; VIRUS REACTIVATION; VIRUS TRANSMISSION; DRUG EFFECT; VIROLOGY;

HUMAN HERPESVIRUS 2;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS;

EID: 73649105839     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.81     Document Type: Editorial

References (16)

1. Looker KJ, Garnett GP, Schmid GP: An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86 (10), 805-812 (2008).
2. Mbopi-Keou FX, Gresenguet G, Mayaud P et al.: Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J. Infect. Dis. 182 (4), 1090-1096 (2000).
3. Brown JM, Wald A, Hubbard A et al.: Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 21 (12), 1515-1523 (2007).
4. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20 (1), 73-83 (2006).
5. Reynolds SJ, Risbud AR, Shepherd ME et al.: Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J. Infect. Dis. 187 (10), 1513-1521 (2003).
6. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L: Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J. Infect. Dis. 169 (5), 956-961 (1994).
7. + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204 (3), 595-603 (2007).
8. McClelland RS, Wang CC, Overbaugh J et al.: Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 16 (18), 2425-2430 (2002).
9. Mole L, Ripich S, Margolis D, Holodniy M: The impact of active herpes simplex virus infection on human immunodeficiency virus load. J. Infect. Dis. 176 (3), 766-770 (1997).
10. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280 (1), 61-66 (1998).
11. Watson-Jones D, Weiss HA, Rusizoka M et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N. Engl. J. Med. 358 (15), 1560-1571 (2008).
12. Celum C, Wald A, Hughes J et al.: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371 (9630), 2109-2119 (2008).
13. Watson-Jones D, Baisley K, Rusizoka M et al.: Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania. Contemp. Clin. Trials (2009) (Epub ahead of print).
14. Celum C, Wald A, Lingappa J et al.: Twice-daily acyclovir to reduce HIV-1 transmission from HIV-1 /HSV-2 co-infected persons within HIV-1 serodiscordant couples: a randomized, double-blind, placebocontrolled trial. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract WELBC101).
15. Lingappa JR, Baeten JM, Wald A et al.: Daily acyclovir delays HIV-1 disease progression among HIV-l/HSV-2 dually-infected persons: a randomized trial. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract WELBC102).
16. Zhu J, Hladik F, Woodward A et al.: Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med. 15 (8), 886-892 (2009).